<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819988</url>
  </required_header>
  <id_info>
    <org_study_id>PSI2008525</org_study_id>
    <nct_id>NCT00819988</nct_id>
  </id_info>
  <brief_title>Pregabalin in the Prevention of Postoperative Delirium and Pain</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety and Efficacy of the Perioperative Administration of Pregabalin in Reducing the Incidence of Postoperative Delirium and Improving Acute Postoperative Pain Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether administration of pregabalin by mouth
      immediately preoperatively and three times daily for 3 days after surgery reduces the
      incidence of delirium postoperatively and improves overall pain control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delirium is a common postoperative complication occurring in up to 73% of patients sometime
      during their hospital stay. Elderly patients undergoing major surgical procedures are at
      highest risk. While many risk factors for delirium are known, the specific pathophysiology of
      postoperative delirium remains unclear and is likely multifactorial. The most common inciting
      agents and events include metabolic causes, medications, blood loss, hypoxemia and pain. Pain
      and its management are intimately related to the likelihood of developing postoperative
      delirium. As a class, gabapentinoids, such as pregabalin, have proven to reduce postoperative
      pain and narcotic consumption and therefore may have a role to play in the prevention of
      postoperative delirium.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delirium (patient is either CAM-ICU positive or positive for delirium by chart review)</measure>
    <time_frame>postoperative day 1, 2, 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interference with daily activities using BPI</measure>
    <time_frame>postoperative day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at rest using NRS</measure>
    <time_frame>postoperative days 1, 2, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain with movement of the operative site using NRS</measure>
    <time_frame>postoperative days 1, 2, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic analgesic requirements</measure>
    <time_frame>postoperative days 0, 1, 2, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation using RSS</measure>
    <time_frame>postoperative days 1, 2, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic-related adverse effects using ORSDS</measure>
    <time_frame>postoperative days 1, 2, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery using the QoR</measure>
    <time_frame>postoperative day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Discharge day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcome Study (MOS) sleep score</measure>
    <time_frame>Postoperative day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Delirium</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 75 mg given 30-60 minutes preoperatively, then 50 mg every 8 hours for 3 days postoperatively if creatinine clearance &gt; 60 ml/min OR 25 mg every 8 hours for 3 days postoperatively if creatinine clearance 30-60 ml/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function</description>
    <arm_group_label>Pregabalin</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 60 years and older

          -  booked for major orthopaedic or vascular procedure

          -  expected length of stay &gt; 2 days

        Exclusion Criteria:

          -  open AAA repair

          -  EVAR

          -  allergy/sensitivity to pregabalin or gabapentin

          -  use of pregabalin or gabapentin in previous 14 days

          -  severe liver disease

          -  severe renal dysfunction defined as either having creatinine clearance &lt; 30 ml/min or
             being dialysis-dependent

          -  seizure disorder

          -  MMSE &lt; 24/30

          -  inability to speak English or French
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan J Chaput, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Homer Yang, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory L Bryson, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Holly Evans, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Beaule, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prasad Jetty, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Power, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990 Dec 15;113(12):941-8.</citation>
    <PMID>2240918</PMID>
  </reference>
  <reference>
    <citation>Bitsch M, Foss N, Kristensen B, Kehlet H. Pathogenesis of and management strategies for postoperative delirium after hip fracture: a review. Acta Orthop Scand. 2004 Aug;75(4):378-89. Review.</citation>
    <PMID>15370579</PMID>
  </reference>
  <reference>
    <citation>Morrison RS, Magaziner J, Gilbert M, Koval KJ, McLaughlin MA, Orosz G, Strauss E, Siu AL. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol A Biol Sci Med Sci. 2003 Jan;58(1):76-81.</citation>
    <PMID>12560416</PMID>
  </reference>
  <reference>
    <citation>Bekker AY, Weeks EJ. Cognitive function after anaesthesia in the elderly. Best Pract Res Clin Anaesthesiol. 2003 Jun;17(2):259-72. Review.</citation>
    <PMID>12817919</PMID>
  </reference>
  <reference>
    <citation>Lynch EP, Lazor MA, Gellis JE, Orav J, Goldman L, Marcantonio ER. The impact of postoperative pain on the development of postoperative delirium. Anesth Analg. 1998 Apr;86(4):781-5.</citation>
    <PMID>9539601</PMID>
  </reference>
  <reference>
    <citation>Gilron I. Review article: the role of anticonvulsant drugs in postoperative pain management: a bench-to-bedside perspective. Can J Anaesth. 2006 Jun;53(6):562-71. Review.</citation>
    <PMID>16738290</PMID>
  </reference>
  <reference>
    <citation>Peng PW, Wijeysundera DN, Li CC. Use of gabapentin for perioperative pain control -- a meta-analysis. Pain Res Manag. 2007 Summer;12(2):85-92.</citation>
    <PMID>17505569</PMID>
  </reference>
  <reference>
    <citation>Leung JM, Sands LP, Rico M, Petersen KL, Rowbotham MC, Dahl JB, Ames C, Chou D, Weinstein P. Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. Neurology. 2006 Oct 10;67(7):1251-3. Epub 2006 Aug 16.</citation>
    <PMID>16914695</PMID>
  </reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2009</study_first_posted>
  <last_update_submitted>January 9, 2012</last_update_submitted>
  <last_update_submitted_qc>January 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ottawa Hospital Research Institute</investigator_affiliation>
    <investigator_full_name>Dr. A. Chaput</investigator_full_name>
    <investigator_title>Clinician Investigator</investigator_title>
  </responsible_party>
  <keyword>Postoperative</keyword>
  <keyword>Perioperative</keyword>
  <keyword>Orthopedic surgery</keyword>
  <keyword>Vascular surgery</keyword>
  <keyword>Gabapentinoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 31, 2017</submitted>
    <returned>March 20, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

